



Vivoryon Therapeutics to Attend and Present at Investor Conferences in November 2019

HALLE (SAALE), Germany, 4 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), announced today that the company is scheduled to attend and present at upcoming conferences in November.

(1) [BIO Europe](#)

November 11-13, 2019; Hamburg Messe, Hamburg, Germany

Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO, to host meetings

Dr. Dauer to present on Monday, November 11, 2019; at 3:30pm CET, in Hall B1, Room 6 on Level 1

(2) [Deutsches Eigenkapitalforum](#)

November 25-27, 2019; Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt, Germany

Dr. Ulrich Dauer, CEO, to host meetings and present on Monday November 25, 2019; at 3:00pm

CET in Room Oslo

###

For more information, please contact:

Vivoryon Therapeutics AG

Dr. Ulrich Dauer, CEO

Email: contact@vivoryon.com

Trophic Communications

Gretchen Schweitzer / Joanne Tudorica

Tel: +49 172 861 8540 / +49 176 2103 7191

Email: schweitzer@trophic.eu / tudorica@trophic.eu

MC Services AG

Anne Hennecke / Susanne Kutter

Tel: +49 (0) 211 529 252 27

Email: vivoryon@mc-services.eu



About Vivoryon Therapeutics AG

With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, PQ912, in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. (www.vivoryon.com)

Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.